Most obesity drugs do not improve quality of life or heart health, analysis indicates

A recent analysis published in *The BMJ* reveals that most obesity medications, including popular treatments like Wegovy (semaglutide) and Mounjaro (tirzepatide), fail to significantly enhance quality of life or demonstrate cardiovascular benefits within a year, despite achieving notable weight loss. The study, which reviewed data from 17 clinical trials involving over 23,000 participants, found that while these drugs led to average weight reductions of 10-15%, improvements in physical and mental health outcomes were minimal. Cardiovascular benefits were observed only in semaglutide, which showed a reduced risk of heart-related events in patients with pre-existing conditions.

The findings highlight a gap between weight loss outcomes and holistic health improvements, raising questions about the long-term value of current obesity therapies. Researchers emphasized that quality of life metrics, such as mobility, emotional well-being, and daily functioning, remained largely unchanged across most trials. Cardiovascular assessments, including blood pressure and lipid levels, also showed limited progress in the majority of cases. The analysis underscores the need for further research into how these medications affect broader health outcomes and whether extended use might yield additional benefits.

The authors caution that while obesity drugs can play a role in weight management, their impact on overall health and disease prevention remains uncertain. They advocate for more rigorous studies to evaluate long-term effects and to develop therapies that address both weight reduction and systemic health improvements. The results also prompt a reevaluation of treatment guidelines, which often prioritize weight loss metrics over patient-reported outcomes or cardiovascular risk reduction.